SEARCH

SEARCH BY CITATION

References

  • Agarwal A. and Danishefsky I. (1986) Requirement of free carboxyl groups for the anticoagulant activity of heparin. Thromb. Res. 42, 673680.
  • Beckman M., Holsinger R. M. and Small D. H. (2006) Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. Biochemistry 45, 67036714.
  • Bergamaschini L., Rossi E., Storini C., Pizzimenti S., Distaso M., Perego C., De Luigi A., Vergani C. and De Simoni M. G. (2004) Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J. Neurosci. 24, 41814186.
  • Buxbaum J. D., Liu K. N., Luo Y., Slack J. L., Stocking K. L., Peschon J. J., Johnson R. S., Castner B. J., Cerretti D. P. and Black R. A. (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273, 2776527767.
  • Cai H., Wang Y., McCarthy D., Wen H., Borchelt D. R., Price D. L. and Wong P. C. (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4, 233234.
  • Cui H., Hung A. C., Klaver D. W., Suzuki T., Freeman C., Narkowicz C., Jacobson G. A. and Small D. H. (2011) Effects of heparin and enoxaparin on APP processing and Abeta production in primary cortical neurons from Tg2576 mice. PLoS ONE 6, e23007.
  • Degenhardt M., Ghosh P. and Watzig H. (2001) Studies on the structural variations of pentosan polysulfate sodium (NaPPS) from different sources by capillary electrophoresis. Arch. Pharm. (Weinheim) 334, 2729.
  • Delehedde M., Lyon M., Gallagher J. T., Rudland P. S. and Fernig D. G. (2002) Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochem. J. 366, 235244.
  • Dudas B., Cornelli U., Lee J. M., Hejna M. J., Walzer M., Lorens S. A., Mervis R. F., Fareed J. and Hanin I. (2002) Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25–35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol. Aging 23, 97104.
  • Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D. and Ward P. J. (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 11221124.
  • Ferri C. P., Prince M., Brayne C. et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 21122117.
  • Glenner G. G. and Wong C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885890.
  • Haass C. and Selkoe D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101112.
  • Haass C., Schlossmacher M. G., Hung A. Y. et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322325.
  • Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., Teplow D. B. and Selkoe D. J. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 88768884.
  • Hileman R. E., Fromm J. R., Weiler J. M. and Linhardt R. J. (1998) Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. BioEssays 20, 156167.
  • Irie A., Yates E. A., Turnbull J. E. and Holt C. E. (2002) Specific heparan sulfate structures involved in retinal axon targeting. Development 129, 6170.
  • Islam T., Butler M., Sikkander S. A., Toida T. and Linhardt R. J. (2002) Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site. Carbohydr. Res. 337, 22392243.
  • Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K. and Muller-Hill B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733736.
  • Kidd M. (1964) Alzheimer's Disease–an Electron Microscopical Study. Brain 87, 307320.
  • Kim H. J., Chae S. C., Lee D. K., Chromy B., Lee S. C., Park Y. C., Klein W. L., Krafft G. A. and Hong S. T. (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J. 17, 118120.
  • Kisilevsky R., Lemieux L. J., Fraser P. E., Kong X., Hultin P. G. and Szarek W. A. (1995) Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1, 143148.
  • Klafki H. W., Wiltfang J. and Staufenbiel M. (1996) Electrophoretic separation of betaA4 peptides (1–40) and (1–42). Anal. Biochem. 237, 2429.
  • Klaver D. W., Wilce M. C., Gasperini R., Freeman C., Juliano J. P., Parish C., Foa L., Aguilar M. I. and Small D. H. (2010) Glycosaminoglycan-induced activation of the beta-secretase (BACE1) of Alzheimer's disease. J. Neurochem. 112, 15521561.
  • Lambert M. P., Barlow A. K., Chromy B. A. et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 64486453.
  • Leveugle B., Ding W., Durkin J. T., Mistretta S., Eisle J., Matic M., Siman R., Greenberg B. D. and Fillit H. M. (1997) Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Neurochem. Int. 30, 543548.
  • Leveugle B., Ding W., Laurence F., Dehouck M. P., Scanameo A., Cecchelli R. and Fillit H. (1998) Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J. Neurochem. 70, 736744.
  • Li B., Lu F., Wei X. and Zhao R. (2008) Fucoidan: structure and bioactivity. Molecules 13, 16711695.
  • Ma Q., Dudas B., Hejna M., Cornelli U., Lee J. M., Lorens S., Mervis R., Hanin I. and Fareed J. (2002) The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. Thromb. Res. 105, 447453.
  • Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L. and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 42454249.
  • Matsuo M., Takano R., Kamei-Hayashi K. and Hara S. (1993) A novel regioselective desulfation of polysaccharide sulfates: specific 6-O-desulfation with N, O-bis(trimethylsilyl)acetamide. Carbohydr. Res. 241, 209215.
  • Mattson M. P. (1994) Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J. Neurobiol. 25, 439450.
  • Meziane H., Dodart J. C., Mathis C., Little S., Clemens J., Paul S. M. and Ungerer A. (1998) Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc. Natl Acad. Sci. USA 95, 1268312688.
  • Milward E. A., Papadopoulos R., Fuller S. J., Moir R. D., Small D., Beyreuther K. and Masters C. L. (1992) The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 9, 129137.
  • Nurcombe V., Ford M. D., Wildschut J. A. and Bartlett P. F. (1993) Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 260, 103106.
  • Paredes-Gamero E. J., Medeiros V. P., Lima M. A. et al. (2012) Chemical reduction of carboxyl groups in heparin abolishes its vasodilatory activity. J. Cell Biochem. 113, 13591367.
  • Patey S. J., Edwards E. A., Yates E. A. and Turnbull J. E. (2006) Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases. J. Med. Chem. 49, 61296132.
  • Petitou M., Herault J. P., Bernat A., Driguez P. A., Duchaussoy P., Lormeau J. C. and Herbert J. M. (1999) Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398, 417422.
  • Saitoh T., Sundsmo M., Roch J. M., Kimura N., Cole G., Schubert D., Oltersdorf T. and Schenk D. B. (1989) Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. Cell 58, 615622.
  • Sanderson R. D., Turnbull J. E., Gallagher J. T. and Lander A. D. (1994) Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J. Biol. Chem. 269, 1310013106.
  • Scholefield Z., Yates E. A., Wayne G., Amour A., McDowell W. and Turnbull J. E. (2003) Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. J. Cell Biol. 163, 97107.
  • Sinha S., Anderson J. P., Barbour R. et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537540.
  • Sisodia S. S. (1992) Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl Acad. Sci. USA 89, 60756079.
  • Sisodia S. S., Koo E. H., Beyreuther K., Unterbeck A. and Price D. L. (1990) Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 248, 492495.
  • Small D. H., Losic D., Martin L. L., Turner B. J., Friedhuber A. and Aguilar M. I. (2004) Alzheimer's disease therapeutics: New approaches to an ageing problem. IUBMB Life 56, 203208.
  • Smith-Swintosky V. L., Pettigrew L. C., Craddock S. D., Culwell A. R., Rydel R. E. and Mattson M. P. (1994) Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J. Neurochem. 63, 781784.
  • Snow A. D., Mar H., Nochlin D., Kimata K., Kato M., Suzuki S., Hassell J. and Wight T. N. (1988) The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am. J. Pathol. 133, 456463.
  • Terry R. D., Gonatas N. K. and Weiss M. (1964) Ultrastructural Studies in Alzheimer's Presenile Dementia. Am. J. Pathol. 44, 269297.
  • Timmer N. M., van Dijk L., van der Zee C. E., Kiliaan A., de Waal R. M. and Verbeek M. M. (2010) Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain A beta levels. Neurobiol. Dis. 40, 340347.
  • Vassar R., Bennett B. D., Babu-Khan S. et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735741.
  • Yan R., Bienkowski M. J., Shuck M. E. et al. (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402, 533537.
  • Zhu H., Yu J. and Kindy M. S. (2001) Inhibition of amyloidosis using low-molecular-weight heparins. Mol. Med. 7, 517522.